Today is a transformative day and the culmination of a great deal of effort and diligence to support the future of PANTHERx. We are very excited to announce that we have taken a significant step towards positioning ourselves for more sustainable growth...

Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Blueprint Medicines as a limited distribution partner for new drug GAVRETO™ (pralsetinib), which was granted -accelerated approval for the treatment...

Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Viela Bio, Inc. as their sole rare pharmacy partner for new drug Uplizna™ (inebilizumab-cdon). The drug has been approved for the treatment of neuromyelitis...

Read the Official PANTHERx Press Release. PANTHERx Rare Pharmacy (PANTHERx), was officially recognized as a prestigious US Best Managed Company for overall business performance and sustained growth. The US Best Managed Company designation, sponsored by...

Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Deciphera Pharmaceuticals as a limited distribution partner for new drug QINLOCKTM (ripretinib). QINLOCK™ is a kinase inhibitor indicated for the...

Read the Official PANTHERx Press Release. PANTHERx Rare Pharmacy (PANTHERx) has again been recognized as the winner of the annual, national Specialty Pharmacy Patient Choice Award™. “We are honored and humbled to be recognized as the top independent specialty...